[Special therapeutic aspects of cryptococcal meningoencephalitis].
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D002648:Child; D003022:Clotrimazole / Q000627:therapeutic use; D003453:Cryptococcosis / Q000188:drug therapy* / Q000276:immunology; D003455:Cryptococcus neoformans / Q000187:drug effects; D004359:Drug Therapy, Combination; D004967:Estrogens / Q000494:pharmacology; D005260:Female; D005437:Flucytosine / Q000627:therapeutic use; D006801:Humans; D007158:Immunologic Techniques; D008297:Male; D008590:Meningoencephalitis / Q000188:drug therapy* / Q000276:immunology; D008825:Miconazole / Q000627:therapeutic use; D008875:Middle Aged; D010587:Phagocytosis; D012293:Rifampin / Q000627:therapeutic use; D014165:Transfer Factor / Q000627:therapeutic use
D000935:Antifungal Agents; D004967:Estrogens; D014165:Transfer Factor; D008825:Miconazole; D000666:Amphotericin B; D005437:Flucytosine; D003022:Clotrimazole; D012293:Rifampin
Aspetti terapeutici particolari della meningoencefalite criptococcica